Commentary By: Steven Sedlis, MD Associate Professor of Medicine, Chief, Division of Cardiology Manhattan Veterans Administration Medical Center
This year’s AHA meeting was held in November in Orlando Florida. The cardiology fellows were …
Category: Cardiology
Clinical Correlations
Breaking News: A Disappointment for Zetia
January 15, 2008
Commentary by Alana Choy-Shan MD, NYU Chief Resident
The highly anticipated results of the ENHANCE trial will likely be presented at the American College of Cardiology meeting in March, but the preliminary results already have …
Evaluation of Asymptomatic Wolff-Parkinson-White EKG Morphology
January 3, 2008
Commentary by David Steckman MD, PGY-2 and William Slater MD, Associate Professor of Medicine, Division of Cardiology
Case: A 42 year-old man presents to clinic for routine follow-up. He is found to …
Vagally-induced Atrial Fibrillation
November 7, 2007
Case by: Alana Choy-Shan, Chief Resident
Commentary by William Slater MD, Associate Professor of Medicine, Division of Cardiology
Following Thanksgiving dinner, a 36 year-old healthy man developed palpitations and heart racing. He was evaluated …
Targeting Triglycerides
October 31, 2007
Commentary by Josh Remick MD, PGY-3
Hypertriglyceridemia is defined by the NCEP guidelines for treatment as a fasting triglyceride level greater than 200 mg/dL after the target LDL-C level has been achieved (1). When triglyceride levels …
Atrial Fibrillation Part 2: Additional Words of Wisdom
August 3, 2007
Commentary by William Slater, MD Associate Professor of Medicine, Divsion of Cardiology
The vast majority of patients with persistent AF can be rendered asymptomatic with AV nodal blocking drugs and don’t require ablation. Digitalis …
Management and Consequences of Atrial Fibrillation
August 2, 2007
Commentary by Timothy Wong, MD
A group of short articles focusing on the consequences and management of atrial fibrillation (AF) recently appeared in the July 7th issue of the Health section of the …
Statin Pleiotropy: Unique Roles for a Common Medication
April 26, 2007
By: Melissa Freeman, MD, PGY1
For over a decade now, statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, have facilitated millions of patients in the management of their atherosclerosis. Statins are known for their ability to reduce hepatic lipoproteins, up-regulate hepatic …